论文部分内容阅读
[目的]探讨利妥昔单抗联合化疗对弥漫大B细胞淋巴瘤(DLBCL)的疗效.[方法]依据不同治疗方案将95例DLBCL患者分为两组,观察组采取利妥昔单抗联合CHOP化疗方案治疗,对照组则给予CHOP方案单纯化疗,比较两组近期疗效、不良反应及治疗前后淋巴细胞亚群变化情况,随访统计两组患者3年生存情况.[结果]①观察组近期总缓解率86.00％(43/50)显著高于对照组的62.22％(28/45)(P 0.05),观察组治疗后B细胞水平显著低于对照组(P 0.05);④观察组随访1年无进展生存率、总生存率分别为 80.00％(40/50)、92.00％(46/50),显著高于对照组的 57.78％ (26/45) ,75.56％ (34/45) (P <0.05),观察组随访3年无进展生存率显著高于对照组(P 0.05).[结论]利妥昔单抗联合化疗相比单纯CHOP化疗能显著提高DLBCL患者近期疗效,明显改善患者无进展生存率,且不增加化疗不良反应,同时对机体T淋巴细胞、NK细胞影响不大,但会导致B淋巴细胞明显降低.“,”[Objective]To investigate the efficacy of rituximab combined with chemotherapy in patients with diffuse large B cell lymphoma (DLBCL).[Methods]According to different treatment regimens, 95 patients with DLBCL were divided into two groups. The observation group was treated with rituximab combined with chemotherapy (CHOP), while the control group was treated with chemotherapy alone. The short-term efficacy,adverse reactions and changes of lymphocyte subsets pre- and post- treatment were compared between the two groups. The 3-year survival rates of the two groups were also calculated.[Results]①The short-term overall response rate of the observation group was 86％ (43/50), which was significantly higher than that of the control group 62.22％ (28/45) (P 0.05),however, the level of B cells in the observation group after treatment was significantly lower than that in the control group (P 0.05). ④During 1-year and 3-year follow-up, the 1-year progression-free survival rate (80％,40/50) and 1-year total survival rate (92％,46/50) of the observation group were significantly higher than those in the control group (57. 78％ and 75.56％,respectively) (P <0.05). The 3-year progression-free survival rate of the observation group was significantly higher than that of the control group (P 0.05).[Conclusion] Compared to chemotherapy (CHOP) alone,rituximab combined with CHOP chemotherapy can significantly improve the short-term efficacy in patients with DLBCL, significantly improve the progression free survival rate, and, furthermore, does not increase the adverse reactions of chemotherapy. The regimen has little effect on T lymphocytes and NK cells though it significantly reduces B lymphocytes.